PHAR — Pharming Group N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1828316 ·
Last close
$10.46
Market Cap
$740.34M
52W High
$21.34
52W Low
$9.62
ADV30
30,553
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 90,213,000 | 75,668,000 | -111,000 | 1,638,000 | 467,984,000 | 158,281,000 | 197,494,000 |
| Mar 2026 | 72,447,000 | 65,803,000 | -5,288,000 | -5,213,000 | 489,365,000 | 52,379,000 | 220,405,000 |
| Dec 2025 | 106,500,000,000 | 85,400,000,000 | 2,000,000,000 | 5,300,000,000 | 499,963,000 | 145,305,000 | 222,861,000 |
| Sep 2025 | 97,287,000 | 90,216,000 | 15,751,000 | 7,548,000 | 473,785,000 | 132,370,000 | 209,141,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$35,027,000
Investing CF
$-85,236,000
Financing CF
$-697,000
CapEx
$-660,000
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-0.18
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-278,245,000
Inventory
$65,428,000
Receivables
$56,980,000
ST Investments
$0
EBIT TTM
$30,561,000
Pretax Income TTM
$15,844,000
Interest Exp TTM
$14,717,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$366,479,008
EBITDA
$32,879,000
Free Cash Flow
$37,686,124
Enterprise Value
$748,436,800
Total Cash
$158,280,992
Total Debt
$113,295,000
Shares Out
70,778,124
Trailing EPS
$0.14
Book Value
$3.82
ROE
3.6%
ROA
3.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 376,134,000 | 20,881,000 | 2,851,000 | 499,963,000 | 222,861,000 | 277,102,000 | 54,708,000 |
| Dec 2024 | 297,200,000 | -3,665,000 | -11,841,000 | 399,985,000 | 178,924,000 | 221,061,000 | -1,795,000 |
| Dec 2023 | 245,316,000 | -22,289,000 | -10,548,000 | 462,854,000 | 244,073,000 | 218,781,000 | -17,302,000 |
| Dec 2022 | 205,622,000 | 9,860,000 | 13,674,000 | 425,797,000 | 221,159,000 | 204,638,000 | 22,458,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.31
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WVE | Wave Life Sciences, Inc. | $744.84M | $3.78 | — |
| SLNCF | Silence Therapeutics plc | $745.85M | $4.00 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $727.09M | $34.45 | — |
| ACRS | Aclaris Therapeutics, Inc. | $758.07M | $5.15 | — |
| DSGN | Design Therapeutics, Inc. | $758.49M | $12.12 | — |
News headlines (Yahoo Finance, 1h cache)
Pharming announces positive Phase II topline data for leniolisib in PIDs with immune dysregulation accepted as late-breaking abstract at ESID 2026
2026-09-22 05:00 · Yahoo
Pharming Group (PHAR) Expands Joenja’s Pediatric Label. Can Growth Offset RUCONEST Weakness?
2026-09-16 22:44 · Yahoo
FDA approves Pharming's Joenja® as first treatment for children with APDS in the U.S.
2026-09-11 18:00 · Yahoo
Pharming Group to participate in September investor conferences
2026-09-09 06:00 · Yahoo
Pharming Group (PHGUF) (Q2 2026) Earnings Call Highlights: Joenja Surges 40% as Ruconest Faces ...
2026-07-30 19:04 · Yahoo
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
2026-09-25 14:30 · Yahoo
Form 8.3
2026-08-14 10:36 · Yahoo
Pharming announces commercial launch of Joenja (leniolisib) in Japan for adult and pediatric patients with APDS aged 4 and older
2026-08-13 05:00 · Yahoo
Pharming Group to participate in Canaccord Genuity 46th Annual Growth Conference
2026-08-04 06:00 · Yahoo
Pharming Group (ENXTAM:PHARM) Could Be 63% Undervalued After Guidance Cut And Half Year Results
2026-08-03 00:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.